anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: To date, a consensus on the relative efficacy and safety of CO2 fractional laser versus erbium-doped yttrium aluminum garnet (Er:YAG) fractional laser treatments for atrophic acne scars has not been reached. This meta-analysis aims to systematically assess and compare their effectiveness and safety in clinical practice.
METHODS: For this meta-analysis, we conducted comprehensive searches in Pubmed, Embase, and Cochrane databases, covering publications from their inception up to August 2023. Our focus was on studies comparing fractional CO2 laser with Er:YAG fractional laser treatments for atrophic acne scars. We excluded duplicate publications, research lacking full-text access, incomplete data, or cases where data extraction was not feasible. Additionally, animal experiments, reviews, and systematic reviews were not considered. Data analysis was performed using STATA 15.1.
RESULTS: Eight studies (seven randomized controlled trials (RCTs) and a retrospective study) were included in this meta-analysis. The sample size ranged from 28 to 106 with a total of 418 patients, including 210 in the CO2 fractional group and 208 in Er:YAG fractional group. The pooled results showed that the effective rate of CO2 fractional laser in treating atrophic acne scar was significantly higher than that of Er:YAG fractional laser (OR = 1.81, 95% CI: 1.08-3.01) and the downtime of CO2 fractional laser in treating atrophic acne scar was significantly shorter than that of Er:YAG fractional laser (Weighted Mean Difference (WMD) = -2.11, 95% CI: -3.11 to -1.10). In addition, VAS of CO2 fractional laser in treating atrophic acne scar was significantly higher than that of Er:YAG fractional laser (WMD = 1.77, 95% CI: 1.32-2.21) and the duration of erythema of CO2 fractional laser in treating atrophic acne scar was significantly longer than that of Er:YAG fractional laser (WMD = 1.85, 95% CI: 1.63-2.07). However, there was no significant difference in the duration of pain and incidence of PIHbetween CO2 fractional laser and of Er:YAG fractional laser.
CONCLUSION: When it comes to treating atrophic acne scars, CO2 fractional laser demonstrates superior efficacy and leads to shorter downtime. However, it is important to note that CO2 fractional laser treatments tend to result in higher pain intensity and may carry a higher risk of post-treatment pigmentation compared to Er:YAG fractional laser procedures.
Meropenem 20 mg/kg per dose (up to 1 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV meropenem only or IV meropenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
A contraceptive anti-human sperm serum for prepg. contraceptive pessaries which immobilises sperm and prevents them reaching the upper parts of the genital tract. The dangers, uncertainty and occasional psychic distress associated with chemical and mechanical contraceptives are avoided. Serum may be prepd. from rabbits horses or other animals which are injected with sperm from young healthy men which is diluted with sterile physiological saline. The collected serum is preserved e.g. by freeze-drying, and powder or tablet forms are enveloped in cocoa butter melting at body temp. to form pessaries.
The participants will identify their accompanying influential person (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. Their accompanying influential person is eligible if they are (a) aged 18 or older and (b) willing to participate in the study.
A significant variation in chromatin accessibility is an epigenetic feature of leukemia. The cause of this variation in leukemia, however, remains elusive. Here, we identify SMARCA5, a core ATPase of the imitation switch (ISWI) chromatin remodeling complex, as being responsible for aberrant chromatin accessibility in leukemia cells. We find that SMARCA5 is required to maintain aberrant chromatin accessibility for leukemogenesis and then promotes transcriptional activation of AKR1B1, an aldo/keto reductase, by recruiting transcription co-activator DDX5 and transcription factor SP1. Higher levels of AKR1B1 are associated with a poor prognosis in leukemia patients and promote leukemogenesis by reprogramming fructose metabolism. Moreover, pharmacological inhibition of AKR1B1 has been shown to have significant therapeutic effects in leukemia mice and leukemia patient cells. Thus, our findings link the aberrant chromatin state mediated by SMARCA5 to AKR1B1-mediated endogenous fructose metabolism reprogramming and shed light on the essential role of AKR1B1 in leukemogenesis, which may provide therapeutic strategies for leukemia.
In recent years, there has been growing interest in understanding the potential role of microbiota dysbiosis or alterations in the composition and function of human microbiota in the development of chronic rhinosinusitis with nasal polyposis (CRSwNP). This systematic review evaluated the literature on CRSwNP and host microbiota for the last ten years, including mainly nasal bacteria, viruses, and fungi, following the PRISMA guidelines and using the major scientific publication databases. Seventy original papers, mainly from Asia and Europe, met the inclusion criteria, providing a comprehensive overview of the microbiota composition in CRSwNP patients and its implications for inflammatory processes in nasal polyps. This review also explores the potential impact of microbiota-modulating therapies for the CRSwNP treatment. Despite variability in study populations and methodologies, findings suggest that fluctuations in specific taxa abundance and reduced bacterial diversity can be accepted as critical factors influencing the onset or severity of CRSwNP. These microbiota alterations appear to be implicated in triggering cell-mediated immune responses, cytokine cascade changes, and defects in the epithelial barrier. Although further human studies are required, microbiota-modulating strategies could become integral to future combined CRSwNP treatments, complementing current therapies that mainly target inflammatory mediators and potentially improving patient outcomes.
Study subjects will receive matching placebo oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
The application relates to the technical field of deep learning, and discloses a method for medical treatment guide, which comprises the following steps: and acquiring a user consultation text, and acquiring a first feature embedded vector corresponding to the user consultation text by using a preset pre-training model. And acquiring a medical knowledge entity corresponding to the user consultation text by using a preset medical knowledge map, and acquiring a second feature embedding vector corresponding to the medical knowledge entity. And performing knowledge fusion by using the first feature embedding vector and the second feature embedding vector to obtain a third feature embedding vector. And determining a diagnosis guide department corresponding to the consultation text of the user according to the first characteristic embedding vector and the third characteristic embedding vector. In this way, by using the first feature embedding vector fusing the context information and the third feature embedding vector fusing the knowledge in the medical knowledge map, a more accurate department of medical guidance can be determined. The accuracy of medical treatment guide is improved. The application also discloses a device, electronic equipment and a storage medium for medical treatment guiding.
The invention belongs to the technical field of biology, and relates to an antibody and an antigen binding fragment thereof for a plasmodium falciparum PfRh5 epitope. It includes framework region FR region, CDR region; the FR region comprises amino acids 1-26, 33-49, 53-88 and/or 98-107 of SEQ ID NO. 1, and amino acids 1-25, 34-50, 59-96 and/or 116-126 of SEQ ID NO. 2; the CDR region of the antibody comprises amino acids 27-32, 50-52 and/or 89-97 of SEQ ID NO. 1 and amino acids 26-33, 51-58 and/or 97-115 of SEQ ID NO. 2. The antibody or the antigen binding fragment is used for detecting the PfRh5 epitope of the plasmodium falciparum or screening corresponding medicines, and is used for clinically preventing or treating plasmodium falciparum related diseases.
Revision hip arthroscopy is an increasingly common procedure as rates of primary hip arthroscopy rise. Etiologies for symptom recurrence may include residual femoroacetabular impingement, cam over-resection, labral pathology, chondral wear, adhesions, and instability. This has spawned sophisticated surgical techniques in hip arthroscopy including labral reconstruction. Indications for labral reconstruction in the revision setting obviously include labral deficiency. In addition, in the absence of other obvious reasons for failure of the primary procedure, a labral reconstruction should be considered for diminutive labra. The ability to predict labral size before surgery based on magnetic resonance imaging can be invaluable.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to phlebology, and can be used to treat varicose veins of the lower limbs. Method comprises puncture of the saphenous vein and insertion into the lumen of the vein under ultrasound control of the micropenal form of sodium tetradecyl sulfate and compression of the sclerosing site. Prepare a microfinal form using two syringes connected through a tee for the infusion system, by mixing the sclerosant solution and atmospheric air in a ratio of 1:4. 0.5 % sodium tetradecyl sulfate solution in the amount of 2.0–5.0 ml is introduced into the micro-form. Immediately thereafter, 0.5–1.0 % sodium tetradecyl sulfate solution is added in an amount of 2.0–5.0 ml in liquid form. Course of treatment is 1-2 procedures of combined sclerotherapy with an interval of 1 to 3 months.EFFECT: method provides reduction in the number of treatment procedures by increasing the volume of sclerosed veins in one procedure with use of a smaller volume of sclerosant in a micro-foam form in combination with the liquid form of the sclerosing agent.1 cl, 1 dwg, 2 ex
The degree of the burn and the rate of scar development during healing are the main determinants of loss of hand function following thermal injury. Compared to adults, managing these injuries in children presents unique challenges due to three factors: (I) children's thin hand skin makes it difficult to protect deep hilar structures; (II) rapid growth of the hand and fingers in the second and third years of life can cause contusion scar deformity; and (III) treatment is frequently challenging due to the young child's lack of cooperation. The manual technique known as Muscle Energy Technique (MET) primarily targets the soft tissues, although it also has significant effects on the muscles. Osteopaths and is currently utilized by a variety of manual therapy professions as a contribution to joint mobilization. This method is also known as the active muscular relaxation technique or the muscle energy technique. Exercise is necessary to maintain mobility, which in turn depends on overcoming dryness and decreased suppleness of the scar tissue across the joint, which in turn depends on preventing joint stiffness. Heat therapy for the relief of joint pain and stiffness was established using paraffin and prolonged stretching. When used as a treatment method, paraffin wax is heated to a temperature between 115 and 118 degrees.

It will be randomized controlled trail. In which convenient sampling technique will be used. Two groups will be formed in which participants will be divided by lottery method. Group A will be treated by paraffin wax bath therapy and Group B treated by paraffin wax bath therapy with muscle energy technique. The result after statistical analysis will either show this intervention is effective or not. Result will be analyzed on SPSS
This pilot study is a prospective, non-randomized clinical trial assessing the safety and feasibility of prostatic artery embolization. Fifty adult male subjects will be enrolled and treated in this study. Patients who provide informed consent and are deemed eligible for participation will undergo prostatic artery embolization in the Interventional Radiology department at the University of Virginia. After performing an angiogram to identify the prostatic arteries, tiny particles known as Embozene Microspheres will be injected into the prostatic artery. Injecting these particles into the prostatic artery will slow blood flow to the prostate and thus shrinking the size of the prostate. By shrinking the size of the prostate, it is hopeful that it will provide relief of lower urinary tract symptoms due to BPH. Subjects will be followed for 2 years as part of their participation in this study.
BACKGROUND: Uterine fibroids are non-cancerous neoplasms that arise from the uterus affecting over 75% of women. However, there is a disparity with Black women having an increased prevalence of nearly 80%. Black women also experience increased symptom burden, including younger age at the time of diagnosis and increased number and volume of fibroids. Less is known about other ethnoracially diverse women such as Latinas and the potential cultural impacts on fibroid burden and treatment.
METHODS: Community engagement studios were conducted to facilitate discussions with stakeholders on their uterine fibroid and menstruation experience. We recruited Black women (n = 6) diagnosed with uterine fibroids and Latinas (n = 7) without uterine fibroids. We held two virtual community engagement studios split by uterine fibroid diagnosis. The studios were not audio recorded and notes were taken by four notetakers. The notes were thematically analyzed in Atlas.ti using content analysis.
RESULTS: Participants felt there was a lack of discussion around menstruation overall, whether in the home or school settings. This lack of menstruation education was pronounced when participants had their first menstruation experience, with many unaware of what to expect. This silence around menstruation led to a normalization of painful menstruation symptoms. When it came to different treatment options for uterine fibroids, some women wanted to explore alternative treatments but were dismissed by their healthcare providers. Many participants advocated for having discussions with their healthcare provider about life goals to discuss different treatment options for their uterine fibroids.
CONCLUSION: Despite uterine fibroid diagnosis, there is silence around menstruation. Menstruation is a normal biological occurrence and needs to be discussed to help prevent delayed diagnosis of uterine fibroids and possibly other gynecological disorders. Along with increased discussions around menstruation, further discussion is needed between healthcare providers and uterine fibroid patients to explore appropriate treatment options.
Best support care is the same as experimental arm. Placebo is take 18 placebo tablets which is the same as K-001 in appearance orally twice a day (morning and evening), 56 days as a cycle.
PURPOSE:To obtain a prazosin preparation useful as an antihypertensive, having prazosin dispersed in an amorphous state in a compounding base, by dissolving prazosin and a specific compounding base in an organic solvent and removing the solvent. CONSTITUTION:Prazosin and one or more compounding bases selected from PVP, PEG, propylene glycol, water-soluble gel high polymer (e.g., hydroxypropyl cellulose, MC, etc.), base soluble in the stomach (e.g., polyvinylacetal diethylaminoacetate, etc.), enteric base (e.g., hydroxypropylmethyl cellulose phthalate, etc.) is dissolved in an organic solvent and the solvent is removed, to give the titled preparation. A blending ratio of prazosin to the compounding base is preferably 1:10 (weight ratio). Prazosin is dispersed and dissolved in an amorphous state in the base and the preparation has more improved solubility and absorption properties than alpha form of prazosin hydrochloride.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic for the scalp and the hair, having excellent effects for reducing a greasy state and smell of the scalp and the hair, and excellent stability with the lapse of time in a preparation shape.  <P>SOLUTION: The cosmetic for the scalp and the hair contains (A) an essence of eucalyptus, (B) a polyhydric alcohol and (C) one or more kinds selected from (c1) an antiseborrheic agent and (c2) an antioxidant. Preferably, (D) a polar oil component is contained therein. Especially, the antiseborrheic agent is preferably selected from an extract of cashew, pyridoxine hydrochloride, an extract of Cuachalalate, clove oil, eugenols, flutamide, 3-deoxyadenosine, cyproteron acetate, 11α-hydroxyprogesterone, chlormadinone acetate, ethynylestradiol, spironolactone and episterone. The antioxidant is preferably selected from an essence of Engelhardtia chrysolepis, an essence of soybean, an essence of black tea, an essence of green tea and an essence of rose fruit.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND: One of the promising methods of influencing the wound process is photobiomodulation (PBM) therapy. The optimal parameters of PBM therapy have not yet been found because the molecular mechanisms of light interaction with tissue are not fully understood.
OBJECTIVE: Studying the influence of PBM of various parameters on the regulation of reparative process- es of chronic wounds using the example of indicators of aggregation activity of platelets, platelet-derived growth factor (PDGF), interleukin-8 (IL-8), and amino-terminal propeptide of type III procollagen (PIIINP) at the remodeling stage. And also the study of the structural and functional features of chronic wound heal- ing in an experiment under various parameters of PBM therapy.
METHODS: Experiments were carried out on Wistar rats. Chronic wounds were simulated. Experimental animals were exposed to PBM at a wavelength of 660 nm and an energy density of 1 J/cm2. In serum, PDGF, IL-8, and PIIINP levels were measured by enzyme-linked immunosorbent assay. The functional activity of platelets was measured using the turbidimetric method. Histological analysis was performed.
RESULTS: The work noted the dose-dependent effect of PBM using the example of platelet aggregation at the remodeling stage during the healing of chronic wounds. The use of PBM therapy resulted in increased serum PDGF levels. Histological examination data indicate a positive effect of PBM therapy on the wound healing process.
CONCLUSIONS: The effectiveness of the use of PBM therapy for the healing of chronic wounds to regulate reparative processes has been proven.
The invention provides a botanical medicine used for treating cancer. The botanical medicine is characterized in that preparation is extracted from Gynura divaricata (L.) DC and the stem and the leaf of Gynura divaricata (Linn.) DC. The root of the Gynura divaricata (L.)DC, the Gynura divaricata (L.)DC belongs to compositae and is embodied in a Traditional Chinese Medicine Dictionary. The Gynura divaricata (L.) DC and the stem and the leaf of Gynura divaricata (Linn.) DC contain more than ten components, including flavonoid, glycoside, terpene and sterols and so on. The medicine technical proposal of the invention is that the preparation is extracted from Gynura divaricata (L.) DC and the stem and the leaf of Gynura divaricata (Linn.) DC and contains the flavonoid, the glycoside, the terpene and the sterols.
BACKGROUND: Venous thromboembolism (VTE) is a well-recognized complication after total joint replacement (TJR). Persons with hemophilia A or B are considered at low postoperative VTE risk due to their coagulation factor deficiencies, and administering pharmacologic thromboprophylaxis is often considered contraindicated. However, using factor replacement therapy could increase the postoperative VTE risk.
OBJECTIVES: To analyze best available evidences of VTE rates in persons with hemophilia A or B undergoing lower limb TJR and the use of postoperative pharmacologic thromboprophylaxis.
METHODS: We systematically screened 4 online biomedical databases to identify studies reporting VTE rates in patients with hemophilia after TJR. Case reports and case series with less than 10 patients were excluded.
RESULTS: Twenty-six observational studies were included in this systematic review, reporting 1181 TJRs in patients with hemophilia A or B. Eight studies had VTE rates as the primary outcome. Five studies reported screen-detected VTE, while 21 reported symptomatic VTE events. Overall, 17 VTE events were reported (1.4%; 95% CI, 0.9%-2.3%), including 10 (6.6%) after 151 surgeries with postoperative VTE screening and 7 (0.7%) after 1080 surgeries without postoperative screening. Thromboprophylaxis protocols were specified in 21 studies; postoperative thromboprophylaxis was used in 15 (1.3%) surgeries. This information was not available for 29.0% of the analyzed population.
CONCLUSION: Despite the low thromboprophylaxis use in patients with hemophilia, rates of symptomatic VTE after TJR appeared to be low. We also highlighted the need to better report the thrombotic outcome in persons with hemophilia to face the ongoing changes in the hemophilia landscape.
Disintegrants are the essential components of a tablet. Cross-linking of dextrin with epichlorohydrin induces hydrophobization in hydrophilic dextrin. This in turn gives good swelling power in water. Dextrin is cross-linked with various ratios of epichlorohydrin to dextrin by weight. Cross-linking is done from 5-50% ratio of epichlorohydrin. The swelling capacity is highest with 20% cross-linking. The cross-linked dextrin is evaluated for disintegrating action by preparation of paracetamol tablets by wet granulation method and folic acid tablets by direct compression technique. In wet granulation technique, tablets prepared using 20% cross-linked dextrin disintegrated in less than one minute and by direct compression technique tablet disintegrated in less than four minutes.